Dr Carsten Kranz | Investigator III
Novartis

Dr Carsten Kranz, Investigator III, Novartis

Carsten Krantz studied Biotechnology at the Mannheim University of Applied Science. After this he moved to Basel to do a PhD in Glycobiology at the Friedrich-Miescher Institute under the supervision of Dr. Jan Hofsteenge to study the glycosylation of Thrombospondin Type I repeats. Subsequently he joined Thermo Fisher Scientific as an application chemist for mass spectrometry to conduct instrument demonstrations on Orbitrap , Iontraps for small and large molecule applications. In 2010 he joined Novartis as a lab head to set up a mass spectrometry laboratory for Biologics. Within Novartis he introduced techniques like immunocapture LC-MS/MS or 2D-LCMS/MS in a regulated DMPK environment to increase sensitivity and throughput. These assays were applied to pre-clinical and clinical assays and also used in regulatory submissions. Since beginning of 2017 Carsten works in the clinical bioanalysis outsourcing department, where he is in charge of outsourcing clinical small and large molecule LC-MS/MS assays as well as ligand binding assays to contract research organizations.

Appearances:



EAC 2017 Day 1, Tuesday 31st October 2017 @ 14:30

Protein LC-MS/MS applied for bioanalytics

  • LC-MS/MS for large molecules offers orthogonality and complementary readouts to traditional ligand binding assays
  • Hybrid LC-MS/MS as the answer to increasing demands in sensitivity?
  • Case studies for pharmacokinetic, pharmacodynamic and immunogenicity studies (PK/PD/IG) by LC-MS/MS
 

back to speakers